Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., ...
Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present quality ...
Astria Therapeutics (NASDAQ:ATXS) Rating Increased to Strong-Buy at Citizens Jmp
Citizens Jmp upgraded shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) to a strong-buy rating in a report published on Friday,Zacks.com reports. Other equities analysts have also recently ...
Astria Therapeutics initiated with an Outperform at JMP Securities
JMP Securities analyst Jonathan Wolleben initiated coverage of Astria Therapeutics (ATXS) with an Outperform rating and $26 price target ...
Buy Rating for Astria Therapeutics: Promising Prospects in HAE and Atopic Dermatitis Markets
Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...
Fintel on MSN3d
JMP Securities Initiates Coverage of Astria Therapeutics (ATXS) with Market Outperform Recommendation
Fintel reports that on January 31, 2025, JMP Securities initiated coverage of Astria Therapeutics (NasdaqGM:ATXS) with a Market Outperform recommendation. Analyst Price Forecast Suggests 244.82% ...
Investing4d
JMP Securities starts Astria Therapeutics stock at Market Outperform
On Friday, JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a price target of $26.00. The stock, currently trading at $7.49 ...
Business Wire12d
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced ...
Investing4d
JMP Securities starts Astria Therapeutics stock at Market Outperform
On Friday, JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a price target of $26.00. The stock, currently trading at $7.49, ...
ETF Daily News9d
Astria Therapeutics’ (ATXS) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) in a research report released on Thursday,Benzinga reports. HC Wainwright currently has a $ ...
Nasdaq6d
JMP Securities Initiates Coverage of Astria Therapeutics (ATXS) with Market Outperform Recommendation
Fintel reports that on January 31, 2025, JMP Securities initiated coverage of Astria Therapeutics (NasdaqGM:ATXS) with a Market Outperform recommendation. As of January 29, 2025, the average one ...